Crescent Biopharma to Present Preclinical Data for CR-001, a PD-1 x VEGF Bispecific Antibody, at the Society for Immunotherapy of Cancer's (SITC) 40th Annual Meeting

Core Insights - Crescent Biopharma is advancing CR-001, a PD-1 x VEGF bispecific antibody, for the treatment of solid tumors, with IND submission expected in Q4 2025 to initiate a global Phase 1 trial in early 2026 [1][3]. Group 1: Product Development - CR-001 combines two validated mechanisms in oncology by blocking PD-1 and VEGF, demonstrating cooperative pharmacology and enhanced T-cell activation in preclinical studies [2][4]. - Preclinical data indicates CR-001 showed potent anti-tumor activity in xenograft mouse models and was well-tolerated in non-human primates [2][4]. - The upcoming presentation at the Society for Immunotherapy of Cancer's 40th Annual Meeting will detail the preclinical development of CR-001 [3]. Group 2: Competitive Landscape - CR-001's mechanism of action is consistent with ivonescimab, which outperformed pembrolizumab in a Phase 3 trial for non-small cell lung cancer, suggesting potential competitive advantages [2][4]. - The anti-VEGF activity of CR-001 may normalize tumor vasculature, potentially enhancing the effectiveness of combination therapies with other antibody-drug conjugates in development [4]. Group 3: Company Vision - Crescent Biopharma aims to establish itself as a leading oncology company by developing transformative therapies for cancer patients, leveraging multiple modalities and established targets [5].